Publication detail

Patients with Type 2 Diabetes Mellitus in the Czech Republic – Estimating Prevalence Based on Consumption of Pharmaceuticals and Their Costs

Author(s): PhDr. Jana Votápková Ph.D., Hroboň, Pavel, Kučová, Petra
Type: Articles in refereed journals
Year: 2017
Number: 4
ISSN / ISBN: 2464-6164
Published in: Ekonomie ve zdravotnictví
Publishing place:
Keywords: diabetes, type 2 diabetes mellitus, prevalence, costs, observational study, population-based study
JEL codes: I11, I18,
Suggested Citation:
Grants: TACR Omega - Type 2 Diabetes Mellitus in the Czech Republic: Cost-of-Illness Study and a Model to Estimate Cost Development (TD03000209) - main researcher
Abstract: Type 2 diabetes mellitus is a widespread disease which represents a serious medical and economic burden worldwide.
We aim to analyze prevalence of type 2 diabetes mellitus in the Czech Republic using individual data on consumption
of pharmaceuticals and to estimate costs incurred by these patients covered by the statutory health insurance.
Prevalence of diabetes in the Czech Republic based on consumption of pharmaceuticals has been growing since 2009.
It reached 5.8% in 2015 and is higher among men than women (5.96% versus 5.65%). Average public annual medical
costs of a patient with type 2 diabetes were CZK 53 thousand in 2015. Total costs of patients with diabetes were CZK
33 billion in 2015, which represents 13% of all healthcare costs covered by the statutory health insurance.
Downloadable: Paper
August 2022
MonTueWedThuFriSatSun
1234567
891011121314
15161718192021
22232425262728
293031    

Partners

Deloitte

Sponsors

CRIF
McKinsey
Patria Finance
Česká Spořitelna
EY